viewOpen Orphan PLC

Venn Life Sciences riding the Biotech wave

AIM listed Venn Life Sciences (LON:VENN) CEO, Tony Richardson, tells Proactive Investors that he expects the solid first half momentum to continue, driven in part by strong demand from Biotechnology companies. He also sees increasing opportunities from medical device companies and mid sized pharmaceutical companies.Venn Life has a solid pipeline of potential opportunities which could be worth up to 18 million Euros. The company provides outsourced clinical contract research services and has recently been winning bigger contracts and taking on more staff. Richardson also sees acquisition opportunities in Central and Eastern Europe.

Quick facts: Open Orphan PLC

Price: 16 GBX

Market: AIM
Market Cap: £87.85 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...



Tiziana Life Sciences, Open Orphan, S4 Capital & planarTECH - Proactive's...

Proactive's head of UK events Thomas Coleman talks Andrew Scott through the line-up at this week's upcoming virtual event. The companies attending include Tiziana Life Sciences PLC (LON:TILS), Open Orphan PLC (LON:ORPH), Sir Martin Sorrell from S4 Capital (LON:SFOR) as well as...

on 04/14/2020

2 min read